June 30, 2016
An Affymetrix shareholder will settle proposed class claims alleging the biotech's $1.3 billion buyout by Thermo Fisher resulted from a curtailed sales process due to a conflict of interest with its financial adviser, Morgan Stanley, according to a letter in California federal court.
February 25, 2016
An Affymetrix shareholder launched a putative class action in California federal court Wednesday, alleging the biotech's $1.3 billion buyout by Thermo Fisher resulted from a "truncated" sales process tainted by a conflict of interest with Affymetrix's financial adviser, Morgan Stanley.